Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perkileucel for anti-PD-1-refractory unresectable or metastatic melanoma
ACTRN12626000394347Phase 2Not yet recruiting
- Sponsor
- East Metropolitan Health Service
- Start
- Apr 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of perkileucel in melanoma, sponsored by East Metropolitan Health Service. Primary endpoint: Activity of TIL ACT in anti-PD-1-resistant unresectable or metastatic melanoma. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
perkileucel
03
Conditions
melanoma
Beyond the preview
Go deeper on ACTRN12626000394347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000394347.